CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 628 enrolled
Drug / intervention
olanzapine +2 moredrug
Likely dose
olanzapine 20 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00337662
NCT00337662Phase 4Completed
CompareCT.gov

Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.

Eli Lilly and Company·interventional·Posted Jun 16, 2006·Updated Feb 17, 2010

In Brief

A Phase 4 clinical trial evaluating olanzapine and risperidone for Schizophrenia and 2 related conditions. Completed, enrolled 628 participants across 34 sites in 3 countries.

Detailed Summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
CountriesArgentina, Russia, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 16, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 20.0 years ago

Interventions

olanzapinedrug

10-20 milligrams (mg), oral, daily, 10 weeks.

risperidonedrug

2-6 mg, oral, daily, for 10 weeks.

risperidonedrug

2-6 mg, oral, daily, 10 weeks